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Abstract
As humans, we cannot regenerate axons within the central nervous system (CNS), therefore, making any damage to
it permanent. This leads to the loss of sensory and motor function below the site of injury and can be crippling to a
person’s health. Spontaneous recovery can occur from plastic changes, but it is minimal. The absence of regeneration
is due to the inhibitory environment of the CNS as well as the inherent inability of CNS axons to form growth cones.
Amongst many factors, one of the major inhibitory signals of the CNS environment is the myelin-associated Nogo
pathway. Nogo-A, Nogo-B and Nogo-C (Nogo), stimulate the Nogo receptor, inhibiting neurite outgrowth by causing
growth cones to collapse through activation of Rho Kinase (ROCK). Antibodies can be used to target this signalling
pathway by binding to Nogo and thus promote the outgrowth of neuronal axons in the CNS. This use of anti-Nogo
antibodies has been shown to upregulate CNS regeneration as well as drastically improve sensory and motor function
in both rats and primates when coupled with adequate training. Here, we evaluate whether the experimental success
of anti-Nogo at improving CNS regeneration can be carried over into the clinical setting to treat spinal cord injuries
(SCI) and their symptoms successfully. Furthermore, we also discuss potential methods to improve the current
treatment and any developmental obstacles.
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Inhibitors of spinal regeneration
It is unclear whether CNS regeneration was an ancestral
trait lost during evolution or an adaptive trait developed
over time. The fact that it is present in fish and some
amphibians would suggest that the trait has diminished
or was lost over time [1]. In the context of survival, CNS
regeneration does not provide a major advantage. If an
animal is unable to move until the spinal cord regener-
ates, then it is vulnerable to attack by predators and un-
able to seek resources. Therefore, it would make sense
to trade regenerative ability for the complexity of con-
nections and more direct motor control from the cortex
seen in higher species. This would allow us to build and
develop alternate strategies for improving survival
chances such as fortified shelters or tools. Humans
undergo extensive neurogenesis during development,
leading to the formation of the most complex and intri-
cate circuits known to man. This fetal plasticity of the
CNS is maintained into neonatal life with extensive re-
covery observed following an injury [2]. Despite this, as
adults, we can only regenerate peripheral nerves to a
certain amount and do not have the ability to reform
CNS connections following a spinal cord injury [3]. Cor-
ticospinal axons will only extend for 1 millimetre caudal
to the injury and so cannot contribute to the recovery
process. The only functional recovery following SCI
comes from sprouting and reorganisation of axons ros-
trally and caudally, as well development of compensatory
movement patterns [4]. This recovery, however, is often
minimal and heavily depends on the extent of the lesion.
Prognosis is best when there is more spared tissue
through which bypass circuits can form.
With no more real danger of predators and developed
healthcare systems, it would be highly desirable to regain
the ability to recover from spinal cord injuries. This is
because such injuries can be extremely debilitating in
everyday life. Damage to axons in the spinal cord means
loss of sensation as well as motor and autonomic out-
puts caudal to the damage. In paraplegic patients, this
means loss of bowel and urinary continence as well as
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the lack of sexual function. Quadriplegic patients can
also experience cardiovascular problems caused by the
loss of the thoracic sympathetic chain [5]. In early days
of treating SCI, most patients died from developing urin-
ary tract infections or pressure sores [6]. In today’s
world, however, most sufferers of spinal cord injury sur-
vive, and the initial damage is minimised. Treatment
now concentrates mostly on controlling bladder dys-
function and neuropathic pain [7]. This is most often
coupled with locomotor training such as walking on a
treadmill [8]. Together modern treatments aim to im-
prove the patient’s quality of life as much as possible,
but with the lack of regeneration in the CNS, there is
only so much that can be done.
There are a number of reasons for this regenerative
disparity between peripheral and central nerves. Initially,
it was believed that CNS axons have an intrinsic inability
to regenerate. However, this has since been disputed
multiple times. Experiments have shown that when the
spinal cord is cut the nerves can regenerate into a per-
ipheral graft demonstrating that CNS axons have at least
some ability to regenerate [9]. The same peripheral
nerve, however, will not regenerate into the CNS, sug-
gesting that the limiting factor is the environment of the
CNS. In the PNS the cut axon degenerates distally to the
cut in an active process known as Wallerian degener-
ation, leaving the sheath and surrounding Schwann cells
to support the growth of the new axon. The proximal
end of the cut then forms a growth cone as the end is
sealed and which can extend using actin filaments [10].
In contrast, in the CNS, the growth cone is prevented
from forming and remaking connections. Firstly, as CNS
neurones mature they stop producing necessary adhe-
sion molecules. In addition, selective transport of mole-
cules into CNS axons means many growth factors are
excluded from the axon reducing the axons overall re-
generative ability [11]. Secondly, a glial scar forms at the
site of injury. This is a protective barrier which reduces
inflammation and allows the blood brain barrier to re-
form. However, it is also physically stops axons from
crossing the site of lesion [12]. The extracellular matrix
of central neurones itself is also quite non-permissive
with many chondroitin sulphate proteoglycans (CSPGs)
forming an impassable mesh [13].
Finally, there are a number of inhibitory signalling
pathways which also cause the collapse of the growth
cone. The idea that the CNS environment was inhibitory
was cemented by Schwab. He showed that neurones
would regenerate into sciatic nerve explants, but not
optic nerve ones, regardless of supplying them with
growth factors [14]. Three years later Caroni and
Schwab found that myelin-associated inhibitors NI-250
and NI-35 were causative of the non- permissive nature
of the CNS [15]. These molecules were later purified,
and DNA sequenced by another group and subsequently
came to be known as Nogo [16].
The gene encoding Nogo has three protein products:
Nogo-A, Nogo-B and Nogo-C. Of these three Nogo-A
was the most potent inhibitor in the CNS with the other
two transcripts of the gene having some peripheral dis-
tribution. Nogo-A has an activating extracellular domain
named Nogo-66 as well as a smaller activating region in
the extracellular N-terminal known as amino-Nogo.
Nogo-66 exerts its main function at the NgR1 receptor
while S1PR2 has recently been identified as the receptor
for amino-Nogo [17]. Though Nogo-A is the strongest
activator of NgR1, it is one of three myelin-associated
proteins along with MAG and OMgp originally thought
to stimulate the receptor [18]. Furthermore, it has now
been shown that CSPGs of the extracellular matrix also
stimulate NgR1 [19]. The binding of all these molecules
to NgR activates a signalling cascade via the Rho family
GTPases which eventually leads to growth cone collapse
[20]. It is now believed that this pathway primarily stabi-
lises connections and limits turnover in the brain in the
transition to adulthood. The decrease in plasticity and
dendritic turnover usually seen in adolescent rats coin-
cides with the appearance of NgR1 ligands. Furthermore,
Nogo knockout mice maintained this plasticity into
adulthood and deletion of NgR1 in adult mice restored
it [21]. Therefore, it could be said that the Nogo path-
way limits rearrangements regardless of whether they
are experience or injury driven [22].
Effects of anti-Nogo therapy
One possible strategy for increasing a central neurones
ability to regenerate would be to block this signalling
pathway thus preventing growth cone collapse. One way
of achieving this would be to use antibodies. Since the
development of monoclonal antibodies, they have been
redesigned to serve as experimental tools as well as tar-
geting a wide variety of signalling pathways. After Caroni
and Schwab first identified the NI-35 and NI-250 mole-
cules they raised antibodies against these to see if this
would promote axonal regeneration [15]. In their experi-
ment, they examined neurite growth in vitro. As optic
nerve explants do not usually support the growth of
neurites in vitro, they first identified parts of the optic
nerve where laminin was present. They knew laminin to
support neurite growth in vitro from experiments using
the sciatic nerve. Despite the presence of laminin around
blood vessels and on the pial membrane no neurite
growth was found after 5 weeks. They went on to treat
these explants with the IN-1 antibody and compared
these to controls where a non-reactive antibody O1 was
used. They found that IN-1 significantly promoted the
growth of sensory and sympathetic neurites into the
optic nerve explant. Their results showed that neurite
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growth of 3 mm or more was witnessed five out of six
times in explants treated with IN-1 compared with one
out of six in control cultures.
However, this study was very limited in its usefulness.
With a small number of nerve explants in vitro, it was
impossible to say at this point whether this would have
any potential in treatment. However, 2 years later the
experiment was performed in vivo. This was achieved by
first implanting young rats with tumours producing IN-
1 and then transecting the cortico-spinal tract [23]. With
all previous studies showing a complete lack of regener-
ation, it was a breakthrough to see IN-1 treated rats with
fine axons extending up seven to 11mm caudal to the
lesion. Massive sprouting was also observed at the site of
the lesion. This contrasts with untreated rats where
similar sprouting occurred though barely ever exceeded
1 mm. Though this study confirmed the effects of the
antibody on neural regeneration in vivo, it still did not
tell us whether it could serve as a potential treatment.
It was not long before another team used IN-1 to in-
vestigate the longevity of these anatomical connections
as well as their potential in functional recovery [24].
Young rats were given a mid-thoracic spinal lesion and
similarly to the previous study mentioned, they were im-
planted with an IN-1 secreting tumour. Rats were then
given 4 to 6 weeks before behavioural training. As
expecting neuronal projections increased caudally and
were also shown to increase in the serotonergic and ad-
renergic systems. These projections persisted for the
whole length of testing surviving 12 weeks. The rats were
later tested for functional recovery against control
healthy rats, lesions only rats, and lesioned rats which
received control antibody.
Contact placing, where neurons extend their axons to
make contact with their target, was completely absent in
the untreated rats as well as those treated with control
antibody. However, in rats treated with IN-1, 80% elic-
ited low threshold contact placing responses. Stride
length was also significantly affected without IN-1 treat-
ment in the limb ipsilateral to the lesion. With treatment
though it was not significantly different to control
healthy rats. Contact placing was later lost following cor-
tical ablation suggesting that the functional recovery was
indeed caused by the regeneration of corticospinal path-
ways. On the other hand, the cortical ablation was found
not to affect the stride length significantly. This would
suggest that pathways controlling stride length do not
originate in the cortex. Instead, this marked improve-
ment in IN-1 treated animals could be due to rewiring
of connections at the level of the brain stem. Unfortu-
nately, in other aspects of motor function, no recovery
was observed. For example, for more precise tasks like
foot placement on grid runways the error rate for IN-1
treated rats and HRP treated rats was the same.
Since then many studies have expanded on this each
time reinforcing the conclusion that anti-Nogo anti-
bodies improve functional recovery. Most importantly,
similar results were reproduced in primates. Monkeys
were required to grab food pellets on a board which re-
quired the opposition of index finger and thumb in both
horizontal and vertical orientations [25]. This was de-
signed to assess their fine finger movements, and dexter-
ity and so is a particularly useful indication of the
clinical usefulness of anti-Nogo treatment. Both horizon-
tal and vertical placing times were significantly reduced
after treatment thus showing that the treatment is
equally effective in higher mammals.
Though the focus of most studies was assessing func-
tional recovery of motor and sensory input, treatment
has been found to improve other effects of SCI as well.
For example, treatment with anti- Nogo antibodies also
reduced muscular spasms usually experienced by people
living with SCI. These most likely arise as a result of the
incorrect wiring of spinal circuitry following injury. Rats
treated with anti-Nogo antibodies had a much lower
prevalence of spasms, and the spasms were less likely to
be triggered when the rats were exposed to cold water.
Though unfortunately, the severity of the spasms was
not significantly different between the groups [26].
There has not been much work concerning the effect of
Nogo in the autonomic system. However, some studies
do suggest an involvement of Nogo in the parasympa-
thetic system. Mice treated with antibodies have been re-
ported to have a better insulin secretion associated with
a higher parasympathetic input and a greater sensitivity
to carbachol [27]. This could mean that following SCI
treatment might improve certain autonomic functions.
In one experiment it was noted that control of bladder
function returned to rats treated with anti-Nogo on
average a week earlier than control groups [28]. Finally,
none of these studies reported any side effects such as
hyperalgesia or allodynia which can often present when
incorrect connections are made in the nervous system.
Thus, results of studies using anti-Nogo have been
very promising. Recovery of motor function has been
consistently demonstrated in rats as well as primates
with fine finger control returning after treatment. Fur-
thermore, no sensory side effects such as hyperalgesia or
allodynia were observed. The treatment also alleviated
other symptoms of SCI such as bladder dysfunction and
muscle spasms making it ideal for application in a clin-
ical setting.
Mechanism of action
Re-lesioning of the spine in Bregman et al. highlighted
that the recovery might not be due to axons growing
through the site of the lesion. Instead, might it be the in-
crease in compensatory pathways that are responsible
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for the increase in functional recovery? Early findings
have revealed that IN-1 indeed increased plasticity in
supraspinal pathways. Following a lesion of the corti-
cospinal tract, both the lesioned and unlesioned fibres
showed appropriate sprouting after applying IN-1. One
team found that after transecting the spinal cord, some
of the transected hindlimb CST axons entered cervical
grey matter where they made connections to short and
long propriospinal axons [29]. They observed that con-
tacts with long propriospinal axons that crossed the le-
sion were maintained over the course of the study.
Retrograde tracing then confirmed that these long pro-
priospinal axons made connections caudally with the
hindlimb motorneurons. This created a new circuit
within the spinal cord which enabled the rats to regain
voluntary control of the hindlimb. The short propriosp-
inal axons were not maintained, however, suggesting se-
lection and maintenance of significant connection.
Pharmacological destruction of these spinal interneurons
was found to abolish the recovery of hindlimb function
[30]. Another team found that rats treated with IN-1
had significantly more fibres crossing the midline at the
level of the red nucleus and pons [31]. These fibres were
shown to originate in the area of the cortex associated
with forelimb movements. The hypothesis that this
crossing over was responsible for recovery was rein-
forced by a repeated lesion to the tract. This should dis-
rupt any regenerating fibres, and it was found not to
have any effect on the functional recovery.
Another study also investigated this possible involve-
ment of the rubrospinal tract in recovery [32]. Following
a lesion and treatment with IN-1, stimulation of the cor-
tex evoked contraction in the forelimb muscle. The in-
creased latency in conduction following a lesion was
suggestive of an increase in the number of synapses be-
tween the cortex and muscle. To test whether this new
pathway involved the rubrospinal tract, both the red nu-
clei were injected with muscimol. This abolished the
forelimb response to electrical stimulation of the cortex
seemingly confirming the involvement of the rubrospinal
tract in reconnecting the cortex to the periphery. They
also found that excitability in the red nucleus has been
increased following the reorganisation of the pathway.
All these findings parallel the pattern of recovery seen in
neonatal rats. Following SCI they show an increase in
sprouting and crossing over of fibres, thus supporting
the hypothesis that Nogo drives the decrease in CNS
plasticity during adolescence.
Next, looking to the motor cortex, it would seem anti-
Nogo treatment does not positively affect reorganisation.
A group of monkeys had the area of the motor cortex
responsible for digit movements mapped [33]. All of the
monkeys had this area of the motor cortex then lesioned
with a group of them receiving anti-Nogo treatment as
well. The treated group showed a considerable improve-
ment in dexterity tests and recovery of hand function.
However, when the cortex was later remapped, there
was no significant difference between any of the mon-
keys. Forearm areas of the cortex were not partly reas-
signed to the digits, and the areas of the lesions that
remained excitable were not related to the degree of
functional recovery.
Thus, recovery of function facilitated by anti-Nogo anti-
bodies is likely caused by rewiring of remaining motor cir-
cuits. With increased plasticity, more fibres can cross over
in the brainstem as well as spinal cord and create new
pathways. Certain movements are affected by repeated
disruption of the CST pathway whereas others seem to be
resistant. This suggests some motor patterns could be
controlled by the rubrospinal pathway following injury
with others relying on the CST forming intraspinal bypass
routes using propriospinal neurones. Therefore, when
treatment strategies should concentrate on maximising
the anti-inhibitory effects in these supraspinal and intrasp-
inal segments of the motor pathways.
Finally, it is important to point out that the first anti-
Nogo antibody, IN-1, is very different from those used
in more recent studies. Neither of these antibodies have
been carefully analyzed for their targets and so it is not
fully known whether the regenerative capacity men-
tioned above is due to i) additional regenerative effects
of the anti-Nogo antibodies (e.g. IN-1) beyond Nogo
neutralization and/ or ii) additional roles of Nogo and
the Nogo receptor beyond growth inhibition. For ex-
ample, IN-1 has been shown to enhance the sprouting of
spared neurons following a lesion and increases the plas-
ticity of surrounding neurons to achieve compensatory
sprouting [34]. Based on the largely intracellular (endo-
plasmic reticulum) localization of Nogo isoforms, they
may be involved in the secretory pathway, such as func-
tioning as chaperones for the trafficking and maturation
of certain proteins. Evidence from He et al. has impli-
cated Nogo-B in the regulation of B-secretase activity
[35], and has been shown to modulate apoptosis, based
on its interaction with pro-apoptotic proteins of the
BCL-2 family [36]. As such, immunotherapy with anti-
Nogo antibodies may have off-target effects and impact
intrinsic neuronal regenerative capacity unrelated to
their inhibitory signalling roles. These unintended effects
may also be responsible for the side effects of IN-1
addition; hyperalgesia has been associated with the aber-
rant growth and sensitization of C, Aδ and Aβ nocicep-
tive fibres, which may be from apoptotic reorganisation
of neural circuits [37].
Factors affecting outcome of therapy
However, increased plasticity and sprouting of axons it-
self is not particularly useful. The correct connections
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must be made and maintained for the new circuits to be
functional. One study showed that when chondroitinase
was used to increase plasticity in lesioned rats only the
ability which was subsequently trained improved. In
contrast, other abilities suffered as untreated rats per-
formed better in tasks which were not included in the
training regime of the treated groups [38]. The different
pathways by which movements can be achieved will
likely compete with each other during spinal and cortical
reorganisation. This could lead to certain areas of the
motor cortex and the patterns they contain to be extin-
guished. Once again, a comparison can be drawn to neo-
natal rats and babies. As mentioned before neonates
exhibit remarkable recovery in motor functions follow-
ing SCI. However, due to areas of cortex competing
against each other, this can lead to permanent deficits in
cognitive abilities.
Another factor to consider when trying to assess the
effectiveness of these antibodies would be how the tim-
ing of the antibody treatment would affect its efficacy.
One study aimed to answer this question by lesioning
thoracic spinal cord in rats then observing the anatom-
ical and functional recovery after delaying treatment
[39]. As a comparison, some rats were still given anti-
Nogo-A antibody acutely as well as control IgG. They
noted that the potential for recovery was decreased as
the delay before treatment increased. The axons regener-
ated over a distance of many millimetres in both the
acute group and one-week delayed group. However,
when treatment was delayed by 2 weeks, this was not
observed. This was mirrored by the functional recovery.
In swimming tests and crossing narrow beams, only the
rats from the acute and one-week delayed group dis-
played significant recovery.
Another study reported that when using soluble NgR to
target the binding domain of Nogo in chronic spinal cord
contusion results were seen even with treatment begin-
ning 4 to 6 months post injury [40]. The treatment did
not promote longer sprouting of corticospinal fibres,
which would be consistent with Gonzenbach et al.’s find-
ings. However, some of the rats became weight bearing,
and an increase of raphespinal axons was observed. This
increase in serotonin fibre density correlated with the
gradual recovery of locomotor functions. These results are
reinforced by the functional recovery of rats which re-
ceived anti-Nogo treatment 9 weeks after ischaemic stroke
[41]. In this group increased crossing over at the red nu-
cleus was observed. However, it should be said in the
studies where treatment was delayed, the improvements
were gradual and of a lesser extent than rats treated
acutely. Nonetheless, more studies should investigate the
optimal window of time for effective treatment.
As we saw from Garcia-Alias et al. dexterity training
had a substantial impact on the recovery of different
functions [38]. We should then consider how this train-
ing should be timed with respect to antibody treatment
and how changing the periodization of training affects
the functional recovery. One experiment subjected a
group of rats to both training and antibody treatment
concurrently, directly after they have been lesioned [42].
They were later compared to a group receiving the anti-
body treatment first then dexterity training after a two-
week delay, as well as two control groups. The group re-
ceiving the antibody treatment parallel with dexterity
scored the worst of all four groups. This group was ob-
served to have an aberrant growth pattern which led to
incorrect motor patterns forming during re-wiring of the
spinal circuitry. The group which was treated first then
trained later performed significantly better than the con-
trols as expected.
Recently it was observed once again that treatment
with anti-Nogo followed by training was the most effi-
cient strategy for increasing recovery after an incomplete
thoracic lesion [43]. Climbing errors and paw dragging
in rats were both reduced which is important as the
CST is crucial in digit movement confirming its involve-
ment in the recovery. Although few fibres reached the
lumbar cord, the group hypothesised that indirect con-
nections caudal to the lesion were responsible for the
restoration of precise paw control. This was reinforced
by the observation of increasing primary afferents and
their connections to motor neurones caudal to the le-
sion. Interestingly, sequential therapy resulted in lower
levels of Ia motor neurone sprouting than the anti-Nogo
therapy on its own similar to Bareyre et al.’s observation
with propriospinal neurones [29]. This was first ex-
plained by Wahl et al.’s group who suggested that se-
quential therapy “may then help to shape the spared and
new circuits by selection and stabilisation of functional
connections and pruning of the non-functional ones
[42]. Lastly, much like other findings so far, no allodynia
or hyperalgesia were reported.
Obstacles to development
As with any field, research should be reproducible to
confirm the findings. Unfortunately, with much research
regarding SCI, this is not the case. When a number of
studies were repeated, most of them did not reproduce
the original results [44]. There is also an ongoing debate
about the genetic evidence for a role of Nogo in inhibit-
ing axon regeneration and plasticity. Investigations have
been performed on mice with targeted disruption of
Nogo and the Nogo receptor, with results ranging from
significant regenerative improvement (supporting anti-
body immunotherapy) to no improvement. For example,
Zheng et al. did not observe any more significant regen-
eration in CST fibre sprouting in Nogo-A/B/C knockout
mice compared with wild type mice [45]. However, other
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teams have shown either significant or moderate fibre re-
generation in young Nogo A/B knockout mice [46, 47].
compare with heterozygous or wild type mice. More re-
cent genetic disruption of the Nogo receptor have shown
similarly disappointing results; Mice with Nogo receptor
deficiency had improved raphespinal and rubrospinal axon
regeneration [48], 2004 and no improvement in terms of
corticospinal regeneration compared with wild type con-
trols [49]. The varying degrees of regenerative capacity of
these mice were attributed to differences in their genetics.
Furthermore, the effect of injury on the spinal cord
and its connections is complex. Increasing plasticity by
itself is useless as connections need to be adequately se-
lected and maintained. Understanding fully how injury
modulates the environment of the spinal cord and how
this might affect the integration of new circuits will be
crucial to furthering our progress.
When studying motor patterns as a measure of recov-
ery, it may be helpful to tailor these to exercises which
utilise the rubrospinal tract. As this is likely one of the
main pathways for recovery of function, the focus of cer-
tain studies could be misleading [50]. Rats have been
found to provide an accurate model for studying human
SCI, with an analogous relationship with respect to func-
tional, electrophysiological and morphological outcomes
[51]. However, when improving upon the details of the
therapy more studies on primates and humans would be
useful. Another problem is that interactions between
Nogo and its multiple receptors are not yet fully under-
stood. Developing our understanding of them could lead
to better treatments being developed, potentially giving
greater alleviation of the growth inhibition. One group
looked to the olfactory system which is one part of the
CNS where extensive neuroplasticity is present under
normal conditions. This study identified a key molecule
in lateral olfactory tract formation which suppressed
Nogo-NgR1 interaction [52]. Understanding the mech-
anism by which LOTUS inhibits Nogo could help de-
velop the antibody treatment. Likewise, LOTUS itself or
derivatives could be used complementarily with the anti-
body treatment. As NgR1 is a common receptor for
most of the molecules in the pathway, it would make a
reasonable target for antibody treatment. One group had
attempted to assess this with an antibody highly selective
for NgR1 [53]. Unfortunately, this produced only modest
increases in functional recovery. Larger improvements
were seen with both peptides targeting NgR anti-Nogo
antibodies [54]. This could be due to cross-activation of
the other receptors in the pathway and perhaps blocking
a larger portion of them could achieve the effect the
group aimed for. Nonetheless, the result was surprising
and highlights the lack of understanding in this field.
In contrast to this, the identification of CSPGs as li-
gands for NgR1 and NgR3 proved more useful. A study
found that the combined treatment using both anti-Nogo
antibodies and chondroitinase was more effective than ei-
ther on their own following a lesion [55]. The rats receiv-
ing combination therapy scored better on both the
staircase and ladder walk test. Digesting CSPGs should in-
crease regeneration itself as well as potentially enhancing
the disinhibition of Nogo. Interestingly the antibodies
stimulated the growth of more large axons whereas chon-
droitinase increase the number of fine fibres. This points
to their difference in function in limiting CNS growth as
well as diminishing inhibitory signals.
Finally, as recovery is usually dependant on the
amount of spared tissue, large lesions tend to have worst
outcomes. This could be improved by pairing antibody
treatment with bridging strategies such as cell grafts.
Furthermore, overcoming the inhibition of the glial scar
or supplying the spinal cord with growth factors could
have additive effects.
Cortical side effects
Finally, and perhaps most importantly, the inhibition im-
posed on the CNS is there for a reason. As was dis-
cussed earlier, the likely function of CNS inhibition is
stabilisation of adult connections. Another potential
function was deduced from mice expressing elevated
levels of NgR1 which had impaired long-term memory
[56]. Administration of soluble Nogo reproduced this
and suppressed long term potentiation (LTP) in the
hippocampus [57]. Could this mean that Nogo treatment
could affect behaviour, and destabilising connections
could potentially lead to aberrant pathways and behav-
iour such as seen in Wahl et al. [42]. None of the other
studies using anti-Nogo-A reported any side effects, but
there is evidence to suggest that negative long-term ef-
fects of upregulated plasticity exist. Hyperactivation of
the mTOR pathway by deletion of the regulator PTEN
leads to increased regenerative sprouting in the CNS.
When this was applied following optic nerve injury a
large number of fibres were misguided and followed
completely incorrect paths [58]. When the same method
was repeated in granule cells of the dentate gyrus, aber-
rant connections formed similar to those in epilepsy and
as expected the rats developed spontaneous seizures
after 4 weeks [59]. More recently in the study carried
out by Akbik et al. it was noted that the increased den-
dritic turnover in the cortex in Nogo knockout mice led
to greater fear extinction on the second day of hearing
unpaired tones [21]. Furthermore, variants of Nogo and
NgR1 have been associated with the development of
schizophrenia in animal models as well as genetic com-
parisons of human variants of the gene [60].
These could be potentially devastating side effects for
patients treated with anti-Nogo mAbs. If such side ef-
fects are observed one way to overcome them would be
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to confine the antibody treatment to the spine and brain
stem. As we have seen from Wyss et al. increased cor-
tical reorganisation is not likely to be responsible for the
improvement in recovery [33]. Therefore if the anti-
bodies could be confined to the brainstem and spinal
cord the therapy should be just as effective. However, if
the antibodies do not reach the cortex behavioural
changes or schizophrenia are very unlikely to be seen.
Using complementary therapies such as cell grafts or
glial scar inhibition would be ideal as they are confined
to the spinal cord. This could mean lower amounts of
antibodies could be used to obtain the same functional
recovery. This could limit the side effects caused by lack
of Nogo-mediated inhibition in the cortex. Perhaps dif-
ferences will be identified in the pathway between the
brain and spinal cord and can be utilised to tailor the
treatment. Already established differences between the
cord and cortex could also be exploited for drug activa-
tion or altering its activity.
Final remarks
The Nogo pathway is most likely responsible for the sta-
bilisation of CNS circuitry during adolescence. As such
it downregulates CNS plasticity and thus the potential
for functional recovery following damage to the spinal
cord.
The use of anti-Nogo targeting antibodies has been
well established to improve anatomical and functional
recovery. Most of the acutely treated rats and monkeys
show major recovery in function with some manual dex-
terity tests revealing no significant difference to healthy
rats. The treatment has also shown to improve associ-
ated deficits in function such as spasms and bladder dys-
function with no reported side effects such as allodynia
or hypersensitivity.
It is now believed that the major way by which sup-
pressing Nogo increases functional recovery is the in-
creased sprouting and bypass pathways in supraspinal
and intraspinal circuitry. Most prominently the increase
in fibres crossing over at the level of the red nucleus as
well as the integration of propriospinal neurones into
motor pathways. Though axonal regeneration through
the site of the lesion has been consistently demonstrated;
this has not been deemed to contribute significantly to
the outcome.
Current evidence suggests most noticeable results after
acute therapy with smaller yet significant effects on re-
covery with the treatment of chronic SCI. This recovery
was most effective when followed with suitable dexterity
training. Increased plasticity in itself is not useful unless
it can be restrained and the new connections effectively
utilised. Furthermore, competition for space during cor-
tical remapping has been shown to result in permanent
deficits in untrained tasks. Therefore, training should
focus on a broad range of motor patterns. Altogether
more investigation will be needed to establish the ideal
regime for treatment and training.
Current development of the treatment would also bene-
fit from a further study of the interactions of the Nogo
pathway as well as the precise mechanisms by which re-
covery is achieved. Moreover, it is becoming clear that the
role of Nogo is limited because of other environmental in-
hibitors associated with the scar. The extracellular matrix
consists of CSPGs and tenascins, organized into a lattice-
like structure called perineuronal nets. After SCI, progres-
sive neurodegeneration occurs through inflammation of
these nets, neuronal and glial apoptosis, glutamate excito-
toxicity, potential disruption of the blood brain barrier,
axonal demyelination and reactive astrogliosis, which all
lead to the formation of an inhibitory glial scar [61]. This
glial scar contributes to the inhibitory environment exist-
ing after injury independent of Nogo. For example, puri-
fied, recombinant myelin-associated glycoprotein (MAG)
and oligodendrocyte myelin glycoprotein have been
shown to collapse axonal growth cones, induce growth
cone retraction and inhibit neurite outgrowth [62, 63].
Furthermore, the inflammatory NF-κB pathway is upregu-
lated downstream of tumor necrosis factor-α, by glial cells
and infiltrated immune cells, producing pro-inflammatory
cytokines, chemokines and activates astrocytes to form
the glial scar which hampers axonal growth across the le-
sion [64]. As such, by understanding the environmental
changes that inhibit plasticity and repair following SCI, we
can identify further targets for therapeutic intervention.
Lastly, Nogo has repeatedly been demonstrated to
affect LTP and memory formation in the hippocampus
with suppression of the pathway leading to increased
fear extinction. Moreover, the Nogo pathway has been
linked to the development of schizophrenia and in-
creased sprouting in the dentate gyrus has been associ-
ated with epilepsy. Therefore, behavioural changes
should be studied to prevent these potential side effects
from developing.
Conclusions
In conclusion, treatment of SCI with anti-Nogo anti-
bodies looks to be moderately promising. It has consist-
ently demonstrated to improve functional recovery after
acute application with no reported side effects, although
genetic evidence for its efficacy is mixed. Although plas-
ticity increases greatly, we need to better our under-
standing of how the new connections are integrated in
order to improve overall outcome. The therapy is also
unlikely to be as effective with more extensive damage
as spare tissue, and therefore potential bypass neurones,
are limited. Lastly, there is growing evidence suggesting
inhibition of the Nogo pathway could have seriously de-
bilitating effects in the cortex. It is highly unlikely that a
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single target immunotherapy (e.g. anti-Nogo) will be
successful; novel therapeutic strategies must confront is-
sues with the extracellular environment of the CNS to
promote both axonal regeneration and functional recov-
ery. With the treatment soon re-entering clinical trials
[65] it will be easier to assess these issues, as effects of
the treatment are studied more thoroughly in humans.
Provided these problems can be solved, overcoming the
permanently debilitating effects of SCI could be a possi-
bility in the very near future.
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